Forskningsområde

Personalized medicine in diabetic kidney disease. Diabetic kidney disease (DKD) is the leading cause of severe chronic kidney disease globally. Despite new therapeutic options for treating DKD, many people experience a progressive loss of kidney function, partly due to large variability in drug response, highlighting the need for more personalization of treatment. However, current markers of DKD - albuminuria and estimated glomerular filtration rate - are insufficient to fully determine the risk of kidney complications and to evaluate and monitor theurapeutic efficacy, and personalizing intervention in DKD requires additional qualified and validated biomarkers.

Aktuel forskning

PRIME-CKD

Currently there are no validated biomarkers (i.e. signal-substances that can be measured in blood or urine) in patients with CKD that aid in guiding optimal therapy for individual patients. Furthermore, there remains a large gap between biomarker research and actual implementation of biomarker based care in daily clinical practice.
Thus, there is an urgent need to validate biomarkers and implement them in daily clinical practice. PRIME-CKD has a unique advantage to address this challenge as it builds on recent discoveries of new biomarkers to help guide optimal treatment to individual patients.